RecruitingPhase 4NCT03982160

L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients

Role of Decreased Nitric Oxide in the Tonic Elevation of Resting Sympathetic Nerve Activity in Chronic Kidney Disease Patients

Sponsor

The University of Texas at Arlington

Enrollment

15 participants

Start Date

Feb 1, 2018

Study Type

INTERVENTIONAL

Conditions

Chronic Kidney Disease

Summary

Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. A potential signal driving sympathetic nerve activity (SNA) involves accumulation of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA). ADMA is elevated in CKD and is a strong, independent predictor of future cardiovascular events in these patients. . The goal of this study is to determine whether overcoming the accumulation of endogenous ADMA with acute L-arginine infusion reduces SNA in CKD patients.

Eligibility

Min Age: 35 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether L-arginine (an amino acid supplement) can reduce overactive nerve signals in the body in patients with moderate chronic kidney disease (CKD). Overactive sympathetic nerve activity in CKD is linked to high blood pressure and heart disease. **You may be eligible if...** - You are between 35 and 75 years old - You have Stage 3 or 4 chronic kidney disease (kidney function is 15–59% of normal) **You may NOT be eligible if...** - You have had a heart attack or heart failure - You have anemia with hemoglobin below 8 g/dL - You have cancer currently being treated - You have had an organ transplant or are on immunosuppressants - You are pregnant, breastfeeding, or currently smoking tobacco - Your heart rate is 100 bpm or above, or your blood pressure is very low (systolic 90 mmHg or below) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.